logo
Plus   Neg
Share
Email

Genentech: FDA Grants Priority Review For Risdiplam - Quick Facts

Genentech, a member of the Roche Group (RHHBY.PK), announced the U.S. FDA has accepted the New Drug Application and granted priority review for risdiplam, an investigational survival motor neuron-2 splicing modifier for spinal muscular atrophy. Previously, the FDA granted Orphan Drug Designation for risdiplam in 2017, followed by Fast Track Designation. The final FDA decision is expected by May 24, 2020.

If approved, risdiplam would be the first at-home administered medicine for people living with spinal muscular atrophy. Genentech leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics, Inc. (PTCT).

The FDA's acceptance of the NDA triggers a $15 million milestone payment to PTC by Roche.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PCNA has recalled about 5,000 units of Spare 10,000 mAh Power Banks for possible fire and burn hazards, the U.S. Consumer Product Safety Commission said in a statement. These include 445 units sold in Canada. The company said the power bank's lithium-ion battery can overheat and ignite, causing fire and burn hazards. Hundreds of Amazon workers have openly criticized the company's record on climate change by intentionally defying a company-wide ban against speaking out. More than 350 employees of the e-commerce giant criticized the company's climate change policy in a Medium blog post Sunday, putting their jobs at risk for violating the company's corporate communications policy. Loneliness at the workplace is on the rise in America and is resulting in less productivity as well as lower retention levels, a new study showed. According to Cigna's 2020 Loneliness Index, three out of five adults, or 61 percent, consider themselves lonely. This represents a seven percentage point increase from 2018. The study surveyed more than 10,400 adults.
Follow RTT
>